|
| 37085425 | Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. | Eur Urol | 2024 |
| 37500339 | Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. | Eur Urol | 2024 |
| 36318705 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 |
| 37526936 | Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. | JAMA Netw Open | 2023 |
| 37585665 | Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? | Future Oncol | 2023 |
| 37220335 | Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. | Am Soc Clin Oncol Educ Book | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37347559 | Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. | J Clin Invest | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36707276 | Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm. | Eur Urol Focus | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36795843 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. | J Clin Oncol | 2023 |
| 36756959 | Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. | J Urol | 2023 |
| 34454807 | Is the Management of Rectal Cancer Using a Watch and Wait Approach Feasible, Safe and Effective in a Publicly Funded General Hospital? | Clin Oncol (R Coll Radiol) | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35405009 | A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. | Cancer Res | 2022 |
| 35439030 | Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? | J Clin Oncol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35538398 | Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. | Prostate | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35714477 | Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. | ESMO Open | 2022 |
| 35656777 | Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. | Future Oncol | 2022 |
| 35446628 | Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). | J Clin Oncol | 2022 |
| 36210299 | A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 36226865 | Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? | Future Oncol | 2022 |
| 35157830 | Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. | Lancet Oncol | 2022 |
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |
| 35179323 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. | N Engl J Med | 2022 |
| 35229141 | Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. | Jpn J Clin Oncol | 2022 |
| 34518652 | Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. | Prostate Cancer Prostatic Dis | 2022 |
| 33420417 | Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. | Prostate Cancer Prostatic Dis | 2021 |
| 33868943 | Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy. | Urol Case Rep | 2021 |
| 33727260 | A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. | Clin Cancer Res | 2021 |
| 33500355 | Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). | Clin Cancer Res | 2021 |
| 33721560 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 34884981 | The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. | Cancers (Basel) | 2021 |
| 34904808 | PARP Inhibition in Advanced Prostate Cancer. | Cancer J | 2021 |
| 34784577 | Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. | Eur J Cancer | 2021 |
| 34478046 | Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). | Target Oncol | 2021 |
| 34286164 | Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience. | Adv Radiat Oncol | 2021 |
| 33373705 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. | Urology | 2021 |
| 33048621 | Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? | J Clin Oncol | 2021 |
| 32345524 | Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer. | Eur Urol | 2020 |
| 34258585 | Accelerating precision medicine in metastatic prostate cancer. | Nat Cancer | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31669135 | Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. | Urology | 2020 |
| 32055002 | Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 31959342 | A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. | Ann Oncol | 2020 |
| 33406057 | PARP inhibitors in prostate cancer: practical guidance for busy clinicians. | Clin Adv Hematol Oncol | 2020 |
| 32807727 | Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. | Eur Urol Oncol | 2020 |